Predicting the oncogenicity of missense mutations reported in the International Agency for Cancer Research (IARC) mutation database on p53
- PMID: 16173033
- DOI: 10.1002/humu.20242
Predicting the oncogenicity of missense mutations reported in the International Agency for Cancer Research (IARC) mutation database on p53
Abstract
Many mutation databases, comprising thousands of reported mutations, are available. Often the clinical significance of the reported mutations is unknown. In this study we developed an algorithm that allows prediction of the clinical significance of missense mutations reported in a mutation database. Nonsense mutations are used as a referent group for this assessment. We used the International Association for Research on Cancer (IARC) mutation database on TP53 to implement the algorithm. First, on the basis of published data [Nachman MW, Crowell SL. 2000. Genetics 156:297-304], we ascribed mutation rates to every single nucleotide substitution (SNS) in the core domain of the TP53 gene. Second, for every possible SNS we computed the expected number of missense mutations, under the assumption that missense mutations are as oncogenic as nonsense ones. The natural logarithm of the ratio of the observed to the expected number of missense mutations (LR) was used as a quantitative measure of oncogenicity (i.e., the ability of a mutation to produce cancer). We estimated the relative oncogenicity of all missense mutations reported in the IARC p53 mutation database, and constructed a profile of oncogenicity of the missense mutations along the DNA-binding region of p53.
Copyright 2005 Wiley-Liss, Inc.
Similar articles
-
The IARC TP53 database: new online mutation analysis and recommendations to users.Hum Mutat. 2002 Jun;19(6):607-14. doi: 10.1002/humu.10081. Hum Mutat. 2002. PMID: 12007217
-
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.Hum Mutat. 2007 Jun;28(6):622-9. doi: 10.1002/humu.20495. Hum Mutat. 2007. PMID: 17311302
-
Missense mutations in cancer suppressor gene TP53 are colocalized with exonic splicing enhancers (ESEs).Mutat Res. 2004 Oct 4;554(1-2):175-83. doi: 10.1016/j.mrfmmm.2004.04.014. Mutat Res. 2004. PMID: 15450416
-
IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer.Hum Mutat. 1999;14(1):1-8. doi: 10.1002/(SICI)1098-1004(1999)14:1<1::AID-HUMU1>3.0.CO;2-H. Hum Mutat. 1999. PMID: 10447253 Review.
-
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.Oncogene. 2007 Apr 2;26(15):2157-65. doi: 10.1038/sj.onc.1210302. Oncogene. 2007. PMID: 17401424 Review.
Cited by
-
PyCogent: a toolkit for making sense from sequence.Genome Biol. 2007;8(8):R171. doi: 10.1186/gb-2007-8-8-r171. Genome Biol. 2007. PMID: 17708774 Free PMC article.
-
Mutational hotspots in the TP53 gene and, possibly, other tumor suppressors evolve by positive selection.Biol Direct. 2006 Jan 31;1:4. doi: 10.1186/1745-6150-1-4. Biol Direct. 2006. PMID: 16542006 Free PMC article.
-
Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers.Nucleic Acids Res. 2014 Dec 1;42(21):12973-83. doi: 10.1093/nar/gku1031. Epub 2014 Nov 5. Nucleic Acids Res. 2014. PMID: 25378323 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous